A Look At Clorox’s Valuation As CEO Linda Rendle Prepares To Step Down

Why Clorox’s CEO transition matters for investors

Clorox (CLX) is back in focus after Chair and CEO Linda Rendle asked the Board to begin a CEO search as she plans to step down for health reasons, drawing attention to potential leadership and policy shifts.

See our latest analysis for Clorox.

The leadership announcement comes after a sharp 1 day share price drop of 6.42% to US$90.02 and a 90 day share price decline of 29.01%. The 1 year total shareholder return is down 28.66%, pointing to fading momentum despite a modest 30 day share price gain of 3.34%.

If this CEO transition has you reassessing your watchlist, it could be a good moment to broaden your search with 20 top founder-led companies

With Clorox trading at US$90.02, sitting at a reported 47% discount to one intrinsic value estimate and about 17% below the average analyst target, is this leadership uncertainty creating a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 22% Undervalued

At a last close of $90.02 versus a most followed fair value of $115.47, the current narrative sees meaningful upside driven by operational and portfolio changes.

The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies, improving supply chain visibility, speeding innovation cycles, and reducing structural costs. These changes should support margin expansion and sustained earnings growth once short-term transition noise normalizes.

Read the complete narrative.

Want to see what this ERP shift and portfolio mix mean for future revenue, margins, and valuation multiples? The underlying narrative leans on a very specific growth path and a tighter profit profile than many might expect.

Result: Fair Value of $115.47 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, slower category growth and heavier price competition in areas like Glad and cat litter could limit the margin and earnings improvements that this upside story assumes.

Find out about the key risks to this Clorox narrative.

Next Steps

With both clear risks and some potential rewards in play, do the current narratives feel too cautious or too optimistic to you? If you want to act promptly and build your own view from the underlying data, start by weighing the 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If this Clorox story has you rethinking your next move, do not stop here. Use data driven stock ideas to pressure test and strengthen your portfolio decisions.

• Target potential upside with companies that look mispriced on fundamentals by checking out 46 high quality undervalued stocks.
• Prioritize resilience and sleep better at night by focusing on 63 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with quality metrics that stack up using the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com